Academica-e. Repositorio Institucional de la Universidad Pública de Navarra
Publicación
Artículo científico (JournalArticle)
Signature-driven repurposing of Midostaurin for combination with MEK1/2 and KRASG12C inhibitors in lung cancer
Drug combinations are key to circumvent resistance mechanisms compromising response to single anti-cancer targeted therapies. The implementation of combinatorial approaches involving MEK1/2 or KRASG12C inhibitors in the context of KRAS-mutated lung cancers focuses fundamentally on targeting KRAS proximal activators or effectors. However, the antitumor effect is highly determined by compensatory mechanisms arising in defined cell types or tumor subgroups. A potential strategy to find drug combinations targeting a larger fraction of KRAS-mutated lung cancers may capitalize on the common, distal gene expression output elicited by oncogenic KRAS. By integrating a signature-driven drug repurposing approach with a pairwise pharmacological screen, here we show synergistic drug combinations consisting of multi-tyrosine kinase PKC inhibitors together with MEK1/2 or KRASG12C inhibitors. Such combinations elicit a cytotoxic response in both in vitro and in vivo models, which in part involves inhibition of the PKC inhibitor target AURKB. Proteome profiling links dysregulation of MYC expression to the effect of both PKC inhibitor-based drug combinations. Furthermore, MYC overexpression appears as a resistance mechanism to MEK1/2 and KRASG12C inhibitors. Our study provides a rational framework for selecting drugs entering combinatorial strategies and unveils MEK1/2- and KRASG12C-based therapies for lung cancer., M.R. was supported by a fellowship
from MICIU (FPU15/00173). The Proteomics Platforms of Navarrabiomed led by E.S.
and J.F.-I. is a member of Proteored, PRB3 and is supported by grant
PT17/0019 of the PE I + D + i 2013¿2016, funded by ISCIII and ERDF. E.J.-L.
was supported by Foundation of Spanish Association Against Cancer
(PROYE18012ROSE), by Centro de Investigación Biomédica en Red
(CIBERONC; CB16-12-00350), and by Generalitat Valenciana (AICO/
2021/333). F.L. was funded by the Gobierno de Navarra (Ref. 34/2021),
the Cancer Research Thematic Network of the Instituto de Salud Carlos
III (RTICC RD12/0036/0066), PID2021-122638OB-I00 MCIN/AEI/
10.13039/501100011033/ FEDER, UE and by FEDER ¿Una manera de
hacer Europa¿. I.F. was funded by FIS PI19/00320 and by the Miguel
Servet Program CP21/00052. S.V. was supported by Ministerio de
Ciencia, Innovación y Universidades, Convocatoria 2019 para incentivar
la Incorporación Estable de Doctores (IED2019-001007-I), by FEDER
/Ministerio de Ciencia, Innovación y Universidades - Agencia Estatal de
Investigación (SAF2017-89944-R and PID2020¿116344¿RB¿100/MCIN/
AEI/10.13039/501100011033, by a Leonardo Grant for Researchers and
Cultural Creators 2018 from BBVA Foundation, by a seed grant at the I
Convocatoria Proyectos Prueba de Concepto from PRB3-Proteored
(Institute of Health Carlos III-ISCIII), by Fundació La Marató de TV3 (474/
C/2019), and by Foundation of Spanish Association Against Cancer -
Strategic Projects 2020 (PROYE20029VICE). M.P.-S. and S.V. were
also funded by Fundación Alberto Palatchi.
Proyecto:
MICINN / Plan Estatal de Investigación Científica y Técnica y de Innovación 2013-2016 T17-0019
,
AEI / Plan Estatal de Investigación Científica y Técnica y de Innovación 2021-2023 PID2021-122638OB-I00
,
ISCIII / Plan Estatal de Investigación Científica y Técnica y de Innovación 2017-2020 (ISCIII) PI19-00320
,
AEI / Plan Estatal de Investigación Científica y Técnica y de Innovación 2013-2016 SAF2017-89944-R
,
MICINN PID2020‐116344‐RB-I00
,
Gobierno de Navarra 34-2021